TWI310766B - Solid salt forms of a pyrrole substituted 2-indolinone - Google Patents

Solid salt forms of a pyrrole substituted 2-indolinone Download PDF

Info

Publication number: TWI310766B
Authority: TW; Taiwan
Prior art keywords: compound; phosphate; solvent; solution; allotrope
Prior art date: 2005-09-19

Application number

TW095134445A

Other languages

English (en)

Chinese (zh)

Other versions

TW200745093A (en

Inventor

Changquan Calvin Sun

Michael Hawley

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-19

Filing date

2006-09-18

Publication date

2009-06-11

2006-09-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-12-16 Publication of TW200745093A publication Critical patent/TW200745093A/zh

2009-06-11 Application granted granted Critical

2009-06-11 Publication of TWI310766B publication Critical patent/TWI310766B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

TW095134445A 2005-09-19 2006-09-18 Solid salt forms of a pyrrole substituted 2-indolinone TWI310766B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71858605P	2005-09-19	2005-09-19

Publications (2)

Publication Number	Publication Date
TW200745093A TW200745093A (en)	2007-12-16
TWI310766B true TWI310766B (en)	2009-06-11

Family

ID=37626412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095134445A TWI310766B (en)	2005-09-19	2006-09-18	Solid salt forms of a pyrrole substituted 2-indolinone

Country Status (24)

Country	Link
US (3)	US20080275101A1 (ru)
EP (2)	EP1928858B1 (ru)
JP (2)	JP4519114B2 (ru)
KR (1)	KR101050906B1 (ru)
CN (2)	CN103601720B (ru)
AR (1)	AR056521A1 (ru)
AU (1)	AU2006293644B2 (ru)
BR (1)	BRPI0616374B8 (ru)
CA (1)	CA2621569C (ru)
CY (1)	CY1109326T1 (ru)
DE (1)	DE602006008015D1 (ru)
DK (1)	DK1928858T3 (ru)
ES (1)	ES2328407T3 (ru)
IL (1)	IL189590A0 (ru)
MX (1)	MX2008002415A (ru)
NO (1)	NO20080866L (ru)
NZ (1)	NZ566033A (ru)
PL (1)	PL1928858T3 (ru)
PT (1)	PT1928858E (ru)
RU (1)	RU2399619C2 (ru)
SI (1)	SI1928858T1 (ru)
TW (1)	TWI310766B (ru)
WO (1)	WO2007034272A1 (ru)
ZA (1)	ZA200801431B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1928858T3 (da)	2005-09-19	2009-10-26	Pfizer Prod Inc	Faste saltformer af et pyrrolsubstitueret 2-indolinon
US20100189788A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline base formulation
CN102858739A (zh)	2010-03-10	2013-01-02	斯索恩有限公司	酰胺化吡咯甲酸酯化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2155187C2 (ru) *	1992-08-06	2000-08-27	Варнер-Ламберт Компани	Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US6574293B1 (en)	1998-10-28	2003-06-03	Ericsson Inc.	Receivers and methods for reducing interference in radio communications
PT1255536E (pt) *	1999-12-22	2006-09-29	Sugen Inc	Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
PT1255752E (pt) *	2000-02-15	2007-10-17	Pharmacia & Upjohn Co Llc	Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
WO2002081466A1 (en) *	2001-04-09	2002-10-17	Sugen, Inc.	Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
DK3168218T3 (en)	2001-08-15	2019-01-14	Pharmacia & Upjohn Co Llc	Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE
MXPA04006992A (es) *	2002-02-15	2004-11-10	Upjohn Co	Procedimiento para preparar derivados de indolinona.
US7452913B2 (en) *	2003-02-24	2008-11-18	Pharmacia & Upjohn Company	Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
US20040209937A1 (en) *	2003-02-24	2004-10-21	Sugen, Inc.	Treatment of excessive osteolysis with indolinone compounds
US20060009510A1 (en) *	2004-07-09	2006-01-12	Pharmacia & Upjohn Company Llc	Method of synthesizing indolinone compounds
DK1928858T3 (da)	2005-09-19	2009-10-26	Pfizer Prod Inc	Faste saltformer af et pyrrolsubstitueret 2-indolinon

2006
- 2006-09-08 DK DK06795470T patent/DK1928858T3/da active
- 2006-09-08 MX MX2008002415A patent/MX2008002415A/es active IP Right Grant
- 2006-09-08 RU RU2008109959/04A patent/RU2399619C2/ru not_active IP Right Cessation
- 2006-09-08 KR KR1020087006545A patent/KR101050906B1/ko active Active
- 2006-09-08 BR BRPI0616374A patent/BRPI0616374B8/pt active IP Right Grant
- 2006-09-08 CA CA2621569A patent/CA2621569C/en active Active
- 2006-09-08 US US12/067,242 patent/US20080275101A1/en not_active Abandoned
- 2006-09-08 SI SI200630386T patent/SI1928858T1/sl unknown
- 2006-09-08 CN CN201310478975.0A patent/CN103601720B/zh active Active
- 2006-09-08 PT PT06795470T patent/PT1928858E/pt unknown
- 2006-09-08 AU AU2006293644A patent/AU2006293644B2/en active Active
- 2006-09-08 PL PL06795470T patent/PL1928858T3/pl unknown
- 2006-09-08 EP EP06795470A patent/EP1928858B1/en active Active
- 2006-09-08 EP EP09165944A patent/EP2112148A1/en not_active Withdrawn
- 2006-09-08 CN CN2006800345053A patent/CN101287724B/zh active Active
- 2006-09-08 ES ES06795470T patent/ES2328407T3/es active Active
- 2006-09-08 DE DE602006008015T patent/DE602006008015D1/de active Active
- 2006-09-08 WO PCT/IB2006/002506 patent/WO2007034272A1/en not_active Ceased
- 2006-09-08 NZ NZ566033A patent/NZ566033A/en unknown
- 2006-09-15 JP JP2006250347A patent/JP4519114B2/ja active Active
- 2006-09-18 TW TW095134445A patent/TWI310766B/zh not_active IP Right Cessation
- 2006-09-19 AR ARP060104101A patent/AR056521A1/es not_active Application Discontinuation
2008
- 2008-02-18 IL IL189590A patent/IL189590A0/en unknown
- 2008-02-18 NO NO20080866A patent/NO20080866L/no not_active Application Discontinuation
- 2008-09-12 ZA ZA200801431A patent/ZA200801431B/xx unknown
2009
- 2009-08-20 CY CY20091100887T patent/CY1109326T1/el unknown
- 2009-12-10 JP JP2009279987A patent/JP2010090152A/ja active Pending
2012
- 2012-02-06 US US13/367,009 patent/US8987320B2/en active Active
2015
- 2015-02-12 US US14/620,835 patent/US9290479B2/en active Active

Also Published As

Publication number	Publication date
DE602006008015D1 (de)	2009-09-03
JP2007084540A (ja)	2007-04-05
CN103601720A (zh)	2014-02-26
AU2006293644A1 (en)	2007-03-29
RU2008109959A (ru)	2009-10-27
BRPI0616374B8 (pt)	2021-05-25
NO20080866L (no)	2008-03-13
TW200745093A (en)	2007-12-16
IL189590A0 (en)	2008-08-07
EP1928858A1 (en)	2008-06-11
BRPI0616374B1 (pt)	2020-05-12
CN101287724A (zh)	2008-10-15
US20080275101A1 (en)	2008-11-06
PT1928858E (pt)	2009-09-17
PL1928858T3 (pl)	2009-12-31
ZA200801431B (en)	2009-07-29
EP2112148A1 (en)	2009-10-28
KR20080037093A (ko)	2008-04-29
AR056521A1 (es)	2007-10-10
ES2328407T3 (es)	2009-11-12
US9290479B2 (en)	2016-03-22
CN103601720B (zh)	2016-08-10
EP1928858B1 (en)	2009-07-22
AU2006293644B2 (en)	2012-05-31
SI1928858T1 (sl)	2009-10-31
BRPI0616374A2 (pt)	2011-06-21
CA2621569A1 (en)	2007-03-29
US20150158849A1 (en)	2015-06-11
HK1125101A1 (en)	2009-07-31
NZ566033A (en)	2011-04-29
CN101287724B (zh)	2013-11-06
DK1928858T3 (da)	2009-10-26
CA2621569C (en)	2010-10-19
CY1109326T1 (el)	2014-07-02
JP4519114B2 (ja)	2010-08-04
MX2008002415A (es)	2008-03-27
WO2007034272A1 (en)	2007-03-29
JP2010090152A (ja)	2010-04-22
US8987320B2 (en)	2015-03-24
US20120142749A1 (en)	2012-06-07
KR101050906B1 (ko)	2011-07-20
RU2399619C2 (ru)	2010-09-20

Publication	Publication Date	Title
TWI746426B (zh)	2021-11-21	(S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR20160040719A (ko)	2016-04-14	피리미딘 화합물을 유효 성분으로 하는 의약 조성물
TW200813026A (en)	2008-03-16	Novel co-crystal
BR112016010041B1 (pt)	2023-04-18	Composto heterocíclico com uma ação inibitória de irak-4, composição farmacêutica, e, uso do composto
JP2013522232A (ja)	2013-06-13	Ｎ−［３−フルオロ−４−（｛６−（メチロキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボサミドの水和結晶性形状
TW201236684A (en)	2012-09-16	Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
WO2014082578A1 (zh)	2014-06-05	杂芳基炔烃化合物及其应用
WO2020244612A1 (zh)	2020-12-10	Cdk9抑制剂的多晶型物及其制法和用途
US9290479B2 (en)	2016-03-22	Solid salt forms of a pyrrole substituted 2-indolinone
WO2021036814A1 (zh)	2021-03-04	吡唑衍生物及其用途
WO2015146928A1 (ja)	2015-10-01	複素環化合物
HK1125101B (en)	2014-07-04	Solid salt forms of a pyrrole substituted 2-indolinone
HK1192226A (en)	2014-08-15	Solid salt forms of a pyrrole substituted 2-indolinone
HK1192226B (en)	2017-09-15	Solid salt forms of a pyrrole substituted 2-indolinone
TWI443096B (zh)	2014-07-01	３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
CN118451071A (zh)	2024-08-06	表皮生长因子受体抑制剂的结晶多晶型物及其组合物和方法
TW202540098A (zh)	2025-10-16	Ｃｄｋ抑制劑的鹽型及固態型

Legal Events

Date	Code	Title	Description
2013-03-11	MM4A	Annulment or lapse of patent due to non-payment of fees